ライフサイエンスコーパス: OGTT

1 OGTT results were available in all patients at baseline,

2 n NGT obese and 11 T2DM subjects received 1) OGTT, 2) euglycemic insulin clamp with muscle biopsy, an

3 in subjects who had a mean (SD) of 6.4 (3.2) OGTTs during 22.1 (8.0) years of follow-up.

4 our blood glucose after glucose overload (2h-OGTT), HbA1c, triglyceride (TG) levels and HOMA-IR and p

5 Of the 585 OGTTs performed on islet cell antibody (ICA)-positive re

6 The proportion of patients with an abnormal OGTT increased from 42% at baseline to 61% at follow-up

7 These pigs were subjected to an additional OGTT at 22 wk.

8 LP-1 levels increased both at fast and after OGTT mainly in type 2 diabetic subjects.

9 42% women, BMI 30 kg/m(2)) before and after OGTT.

10 2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were significantly lo

11 lic acid cycle intermediates decreased after OGTT, and glycolysis products increased, consistent with

12 in mean (SEM) insulin AUC 120 minutes after OGTT (-2930 [912] vs -414 [432] microIU/mL [-20349 6334

13 An OGTT and IVGTT were repeated during the 12th week of tre

14 0.33, P = 0.02), insulin secretion across an OGTT (men R = 0.46, P = 0.01; women R = 0.40, P = 0.004)

15 mately 50% to the insulin excursion after an OGTT with and without DPP-4 inhibition.

16 e-phase insulin secretion, as revealed by an OGTT.

17 e area under the curve for glucose during an OGTT, and liver fat.

18 ell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosigl

19 d the inclusion criteria, of whom 122 had an OGTT (91% of cohort).

20 n 5.6 and 6.9 mmol/L were invited to have an OGTT.

21 These findings suggest routine use of an OGTT in renal transplant recipients is a valuable clinic

22 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2

23 athways that are perturbed in response to an OGTT.

24 ned with periodic metabolic testing using an OGTT.

25 The estimation of beta-cell function with an OGTT before surgery can identify patients at risk for de

26 ternational Diabetes Federation criteria and OGTT was interpreted according to the WHO classification

27 Fasting, 24-h, and OGTT insulin levels were similar between groups througho

28 999 to 2011, measurements of fPG, HbA1c, and OGTT were performed in 1,619 nondiabetic renal transplan

29 Intravenous glucose tolerance test IVGTT and OGTT insulin secretion rate (ISR) and sensitivity were o

30 ctisole was included in both the preload and OGTT solutions.

31 s rs1799884 (GCK) and rs7903146 (TCF7L2) and OGTT outcomes at 24-32 weeks' gestation in 3,811 mothers

32 ovariates, maternal body mass index (BMI) at OGTT, maternal height at OGTT, maternal mean arterial pr

33 mass index (BMI) at OGTT, maternal height at OGTT, maternal mean arterial pressure at OGTT, maternal

34 ovariates, maternal glucose and C-peptide at OGTT.

35 at OGTT, maternal mean arterial pressure at OGTT, maternal smoking and drinking; Model 3 adjusted fo

36 HbA1c, basal OGTT, and 1- and 2-hour OGTT were positively related to

37 Because of the lack of agreement between OGTT results and HbA1c levels, models were created to an

38 Other pathways affected by OGTT included decreases in serotonin derivatives, urea c

39 nd one of four cases of PTDM was detected by OGTT alone.

40 dless of the diagnosis of IGT or diabetes by OGTT.

41 tolerance, especially for IGT and new DM by OGTT compared with AIR.

42 ique metabolic phenotypes can be unmasked by OGTT in the prediabetic state.

43 y rate (P = 0.020) compared with the control OGTT.

44 Combining 3- and 12-month data, OGTT recorded NODAT in 14% and impaired glucose toleranc

45 72 showed association with 30' Deltainsulin (OGTT 30' min fasting insulin) in an interaction with per

46 mal OGTTs (NLOGTT), while transient diabetic OGTTs (TDOGTTs) were compared with subsequent nondiabeti

47 During OGTT, 18 patients who had a blood glucose nadir of <69 m

48 During OGTT, cortisol and DHEA increased after the third hour a

49 During OGTT, glucose area under the curve (AUC) was higher and

50 During OGTT, IT-operated animals exhibited lower plasma glucose

51 During OGTT, we measured hepatic (HGU) and adipose tissue (ATGU

52 20 min (fold change glucagon120/0 <1) during OGTT, whereas 21-34% presented with increasing glucagon

53 er SI higher glucose and insulin AUCs during OGTT, and higher triglyceride levels, independent of tot

54 sma glucose and 1-hour plasma glucose during OGTT.

55 for 0-120 min for glucose and insulin during OGTT, Quantitative Insulin Sensitivity Check Index, Simp

56 reduces plasma free fatty acid levels during OGTT.

57 Glucagon levels were measured during OGTT in a total of 4,194 individuals without diabetes in

58 nsulin, and c-peptide values measured during OGTT.

59 o quantify insulin-secretory profiles during OGTT and glucose infusion protocols.

60 0-min but not 30-min insulin response during OGTT.

61 ressive impairment in FFA suppression during OGTT, whereas the rise in mean plasma glucose concentrat

62 ps), the change in total glucose area during OGTTs (P = 0.58), or the change in fractional glucose di

63 mental insulin response (30-min dINS) during OGTTs.

64 ant (P < 0.001), and with a reduction during OGTTs, which approached statistical significance (P = 0.

65 Dysglycemic OGTTs (DYSOGTTs) were compared with normal OGTTs (NLOGTT

66 s compared with control HF animals following OGTT.

67 obtained 2 h after a glucose load given for OGTT (r = 0.69, P = 0.001).

68 itivity more than 94%, avoiding the need for OGTT in 49% of patients.

69 velop diabetes during the trial returned for OGTTs and IVGTTs 8 months after study medications were s

70 plasma glucose concentration from the 100-g OGTT at which GDM was diagnosed (higher = increased risk

71 remental insulin:glucose ratio during a 75-g OGTT (P = 0.0002) and the total area under the diagnosti

72 ental plasma insulin:glucose ratio on a 75-g OGTT and the insulin sensitivity index from a hyperinsul

73 Ten minutes before the 75-g OGTT, participants consumed a preload solution of either

74 85 nondiabetic British subjects after a 75-g OGTT.

75 between 1 and 6 months postpartum for a 75-g OGTT.

76 the increment in plasma insulin to glucose [OGTT/IR (DeltaI/DeltaG / IR)]).

77 n 87 subjects, and diabetes was found by 2-h OGTT criteria alone in 61 subjects.

78 jects with IGT and subjects diagnosed by 2-h OGTT criteria alone.

79 hen substituting alpha-HB and L-GPC with 2-h OGTT glucose concentrations.

80 ired glucose tolerance, with fasting and 2-h OGTT insulin values increasing by 2.3-fold (P < 0.001) a

81 However, both basal and 2-h OGTT serum insulin were significantly correlated with SA

82 of HbA1c (beta = 0.08%; P = 0.03) and 2-hour OGTT glucose concentrations (beta = 0.25 mmol/L; P = 0.0

83 VLDL cholesterol, triglycerides, and 2-hour OGTT were higher in patients with periodontitis than in

84 HbA1c, basal OGTT, and 1- and 2-hour OGTT were positively related to prepregnancy BMI and blo

85 HbA1c, triglycerides, and 1- and 2-hour OGTT were positively related with probing depth and clin

86 hirteen Glut1-DS patients completed a 5-hour OGTT.

87 No significant changes in OGTT responses were observed.

88 dition, there was a trend for a reduction in OGTT insulin area under the curve (-15,567 +/- 3,658 pmo

89 be different genes influencing variation in OGTT measures of insulin secretion and insulin resistanc

90 ams/L), basal glucose (-0.9 +/- 0.8 mmol/L), OGTT glucose area under the curve (-158 +/- 164 mmol/L),

91 els increased overall from the first to last OGTTs before diagnosis (P < 0.001 at every time point, n

92 We evaluated Adipo-IR (fasting and mean OGTT plasma free fatty acid [FFA] x insulin concentratio

93 owever, the insulin response (IGR) at 60-min OGTT was significantly lower in T-allele carriers (P = 3

94 ever, the nutrient-induced delta (meal minus OGTT) in insulin secretion and glucagon concentrations d

95 sted of 53 living subjects who had 2 or more OGTTs and underwent brain 11C-PiB positron emission tomo

96 Of 135 progressors with four or more OGTTs, 30 (22%) went from NLOGTTs to DYSOGTTs at least t

97 and subsequent (within 3 months) nondiabetic OGTTs in 55 progressors.

98 s) were compared with subsequent nondiabetic OGTTs and with OGTTs performed at diagnosis.

99 c OGTTs (DYSOGTTs) were compared with normal OGTTs (NLOGTT), while transient diabetic OGTTs (TDOGTTs)

100 n sensitivity, as illustrated by a return of OGTT glucose and insulin values and maximal GDR to near-

101 ant recipients and supports continued use of OGTT as a diagnostic tool for detection of PTDM.

102 nderwent transplant surgery within 1 year of OGTT and had a repeat OGTT 3-6 months after transplantat

103 re measured concurrently with performance of OGTTs in the same study.

104 iabetes was diagnosed by the 2-h criteria on OGTT alone.

105 demonstrated associations with at least one OGTT trait in nondiabetic individuals; 80 SNPs were nomi

106 After baseline oral (OGTT) and intravenous (IVGTT) glucose tolerance testing,

107 at which time 4 p.m. CapBG also outperformed OGTT.

108 men provided data from a total of 280 paired OGTTs and IVGTTs during a median follow-up of 46 months.

109 status was assessed by fasting and 2-h post-OGTT glucose and glycated hemoglobin (HbA(1c)).

110 respectively (P for trend = 0.003); 2-h post-OGTT glucose: 106.3 and 101.9 mg/dL, respectively (P for

111 and glycemic status, as measured by 2-h post-OGTT insulin and glucose and ISI(0,120), after adjustmen

112 characteristics, and diet quality [2-h post-OGTT insulin: lowest and highest quintile, 81.0 and 72.7

113 Among 205 participants with previous OGTT data, greater severity and longer duration of hyper

114 Prolonged OGTT in four available patients and matched control subj

115 rgery within 1 year of OGTT and had a repeat OGTT 3-6 months after transplantation.

116 ying HbA1c as a screening test and reserving OGTT for those with impaired glucose tolerance would det

117 luster and response to an oral glucose test (OGTT) and oral fat load test (OFTT) in the EARSII group

118 betic by a 75-g oral glucose tolerance test (OGTT) (65 had NGT and 60 had IGT).

119 had an abnormal oral glucose tolerance test (OGTT) (P = 0.03) before and a higher frequency of oral h

120 and the average oral glucose tolerance test (OGTT) 2-h glucose measurement over previous BLSA visits.

121 sted with a 5-h oral-glucose-tolerance test (OGTT) and a euvolemic, euenergetic protein challenge.

122 henotyped by an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test and by a

123 essed during an oral glucose tolerance test (OGTT) and an isoglycemic intravenous glucose clamp (iso-

124 received a 75-g oral glucose tolerance test (OGTT) and euglycemic insulin (80 mU x m(-2) x min(-1)) c

125 nce received an oral glucose tolerance test (OGTT) and euglycemic insulin clamp.

126 rance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were perfor

127 se infusion and oral glucose tolerance test (OGTT) before and 6 months after RDN.

128 ting, 24-h, and oral glucose tolerance test (OGTT) blood glucose, plasma insulin, and C-peptide level

129 ption during an oral glucose tolerance test (OGTT) for 400 northern European mothers at approximately

130 fasting and 2-h oral-glucose-tolerance test (OGTT) glucose and insulin concentrations were also measu

131 confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of gestation, but it is still un

132 (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessions.

133 sured during an oral glucose tolerance test (OGTT) in 552 nondiabetic participants in the Amish Famil

134 hanges after an oral glucose tolerance test (OGTT) in a community-based population.

135 e meal than the oral glucose tolerance test (OGTT) in all subgroups regardless of whether they had ab

136 efficacy in an oral glucose tolerance test (OGTT) in lean mice.

137 activity in an oral glucose tolerance test (OGTT) in normal and diabetic mice.

138 ds and after an oral glucose tolerance test (OGTT) in the European Atherosclerosis Research Study II

139 nderwent a 75-g oral glucose tolerance test (OGTT) in which we measured glucose tolerance, IR, and su

140 ng and 2-h post-oral-glucose-tolerance test (OGTT) insulin, the homeostasis model assessment of insul

141 subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days with the use of a randomized cr

142 itivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments.

143 hour and 2-hour oral glucose tolerance test (OGTT) results, with measurement of glucose and insulin l

144 e results of an oral glucose tolerance test (OGTT) routinely performed before surgery and 1 and/or 5

145 imals during an oral glucose tolerance test (OGTT) such that levels were indistinguishable from those

146 y was to use an oral glucose tolerance test (OGTT) to risk stratify for NODAT and IGT in renal transp

147 ciations with 5 oral glucose tolerance test (OGTT) traits in 427 nondiabetic Amish subjects, and 2) i

148 response to an oral glucose tolerance test (OGTT) was not affected.

149 weekly, and an oral glucose tolerance test (OGTT) was performed at study's end.

150 The 5-hour oral glucose tolerance test (OGTT) was performed to assess cerebral function and syst

151 OT) results, an oral glucose tolerance test (OGTT) was performed to diagnose GDM.

152 An oral glucose tolerance test (OGTT) was used to evaluate glucose control 3 weeks after

153 GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose t

154 (IGR) at 30-min oral glucose tolerance test (OGTT), a frequently used surrogate of first-phase insuli

155 nd underwent an oral glucose tolerance test (OGTT), a hypoglycemia questionnaire, and continuous gluc

156 AUCs) during an oral glucose tolerance test (OGTT), and blood lipids in the two groups before and aft

157 els in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chronic dosing.

158 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydrochlorothiazide an

159 responses to an oral glucose tolerance test (OGTT), insulin sensitivity evaluated via hyperinsulinemi

160 ) underwent 5-h oral glucose tolerance test (OGTT), isoglycemic intravenous glucose infusion, and gra

161 ein we describe oral glucose tolerance test (OGTT)-modeled beta-cell function and incretin effect in

162 rarely utilized oral glucose tolerance test (OGTT).

163 studied with an oral glucose tolerance test (OGTT).

164 responses to an oral glucose tolerance test (OGTT).

165 )) underwent an oral glucose tolerance test (OGTT).

166 ns after a 75-g oral glucose tolerance test (OGTT).

167 s before a 75-g oral glucose tolerance test (OGTT).

168 g/dL) during an oral glucose tolerance test (OGTT).

169 0 min before an oral glucose tolerance test (OGTT).

170 tested after an oral glucose tolerance test (OGTT).

171 erived from the oral glucose tolerance test (OGTT).

172 subjected to an oral glucose tolerance test (OGTT); blood glucose increased (P<0.05) in control pigs

173 maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for Model 1 covariates, maternal

174 glucose from an oral glucose tolerance test [OGTT] [DM2h], n = 80; newly diagnosed diabetes by fastin

175 acterized by oral glucose tolerance testing (OGTT) and National Diabetes Data Group criteria.

176 Oral glucose tolerance testing (OGTT) has been mooted as an alternative but is inconveni

177 derwent 75-g oral glucose tolerance testing (OGTT), body composition analysis (dual-energy X-ray abso

178 ls underwent oral glucose tolerance testing (OGTT).

179 ents underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (baseline) and then in 2011 to 201

180 gone 2 or more oral glucose tolerance tests (OGTT) using grouped analyses and a continuous mixed-mode

181 explored with oral glucose tolerance tests (OGTT), serum lipid profiles, magnetic resonance imaging

182 mol/l on their oral glucose tolerance tests (OGTT).

183 glucose and/or oral glucose tolerance tests (OGTT).

184 ral and intravenous glucose tolerance tests (OGTT; IVGTT), hyperinsulinemic-euglycemic clamps, and me

185 sampled intravenous glucose tolerance tests (OGTTs and FSIGTs), hyperinsulinemic-euglycemic clamps wi

186 , we performed oral glucose tolerance tests (OGTTs) and euglycemic-insulinemic clamp studies in Zucke

187 Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolera

188 Oral glucose tolerance tests (OGTTs) and intravenous glucose tolerance tests (IVGTTs)

189 Oral glucose tolerance tests (OGTTs) from differing states of glycemia were compared w

190 se levels from oral glucose tolerance tests (OGTTs) in pregnancy have not been assessed in a large sa

191 3 months, and oral glucose tolerance tests (OGTTs) were performed annually to detect diabetes.

192 Oral-glucose-tolerance tests (OGTTs) were performed before and immediately after the d

193 underwent 5-h oral glucose tolerance tests (OGTTs), graded glucose infusion, and hyperinsulinemic-eu

194 lucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postchallenge glucagon

195 tered prior to oral glucose tolerance tests (OGTTs).

196 uently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29 recruited participants complet

197 nd correlated with glucose levels across the OGTT (R = 0.44, P < 0.001) but was independent of fat ma

198 Although the OGTT is the "gold standard" for diagnosing diabetes, it

199 The ingestion of saccharin before the OGTT did not alter any of the measured variables but eli

200 [(18)F]2-fluoro-2-deoxy-d-glucose before the OGTT, and the rate of glucose absorption (RaO) and dispo

201 +/- 5 mg/dl), mean plasma glucose during the OGTT (290 +/- 9 to 225 +/- 6 mg/dl), HbA(1c) (8.5 +/- 0.

202 than G(L)-overexpressing HF rats during the OGTT (419 versus 117 microg of glycogen/mg of protein, r

203 6 +/- 50 micro Eq/l) and mean FFA during the OGTT (644 +/- 41 to 471 +/- 35 micro Eq/l) (both P < 0.0

204 e responses over the first 30 min during the OGTT (DeltaI(30)/DeltaG(30)).

205 earance both fasting (r=0.34) and during the OGTT (r=0.40, all P <0.002).

206 es in glucose or insulin measures during the OGTT between the 2 groups, but there was a trend for imp

207 n indexes were reduced (P < 0.01) during the OGTT in the impaired glucose tolerance groups, indicatin

208 e increased and their suppression during the OGTT was impaired.

209 nsulin area under the curve (AUC) during the OGTT was significantly reduced after 6 months of DHEA th

210 emic profile and insulin response during the OGTT were normal.

211 ups of obese mice, glucose levels during the OGTT were substantially increased compared with those in

212 Based on the C-peptide response during the OGTT, increased CHO-induced insulin secretion is one pos

213 beta-Cell function during the OGTT, significantly blunted prior to RYGBP, normalized t

214 qual amounts of CHO were consumed during the OGTT, the MUFA group had significantly higher C-peptide

215 cterize nonsuppressed glucagon120 during the OGTT.

216 to or greater than those present during the OGTT.

217 ured at baseline and every 30 min during the OGTT.

218 (P=0.004 and 0.07, respectively) during the OGTT.

219 ncentration curves, respectively, during the OGTT.

220 nd the insulin secretory response during the OGTT.

221 eased and triglycerides increased during the OGTT.

222 insulin-deficient Gcgr(-/-) mice during the OGTT.

223 agon concentrations were measured during the OGTT.

224 DJB improved the OGTT significantly (P < 0.001) compared with sham-operat

225 at of glucose during the first 30 min of the OGTT (delta IRI[30 min-0 min]/delta glucose[30 min-0 min

226 in effect was calculated as the ratio of the OGTT-betaCGS to the 2-h hyperglycemic clamp-betaCGS.

227 ty was 100% compared with the results of the OGTT.

228 his value, regardless of the findings on the OGTT.

229 t eliminated the effects of lactisole on the OGTT.The pharmacologic inhibition of STRs in the gastroi

230 Since the OGTT studies were performed on 20-h fasted rats, this me

231 cagon ratio.The addition of lactisole to the OGTT caused increases in the plasma responses of insulin

232 When this cutpoint was reapplied to the OGTT results, of those subjects with an HbA1c level of a

233 The large increase of ISR response to the OGTT together with the restoration of the first-phase in

234 the C-482T (IRE) determined response to the OGTT, with carriers of the rare T-482 having significant

235 d a full neuropsychological battery prior to OGTT.

236 entially affect postprandial and response to OGTT and suggest a novel mechanism for the effects of va

237 ased 67% (28 weeks), and insulin response to OGTT was decreased by 50%.

238 fect and inappropriate glucagon responses to OGTT.

239 m 3 months, HbA1c had similar sensitivity to OGTT and represents a convenient alternative.

240 enotyped for the E23K variant also underwent OGTTs.

241 s detected in 46% with CapBG versus 12% with OGTT (P=0.013), 4% with HbA1c (P<0.001), and 0% with FPG

242 as present in 14% with HbA1c versus 20% with OGTT (P=0.600) and 2% with FPG (P=0.059; n=50), whereas,

243 AT was found in 4% with HbA1c versus 6% with OGTT (P=1.00) and 2% with FPG (P=0.618; n=51).

244 rs2237457 was also strongly associated with OGTT glucose area under the curve in nondiabetic subject

245 olites tested, 91 significantly changed with OGTT (P </= 0.0005 for all).

246 71, located in FHIT) showed replication with OGTT traits and also in another population.

247 fore, MS has to be considered in tandem with OGTT results to assess cardiovascular risk.

248 d with subsequent nondiabetic OGTTs and with OGTTs performed at diagnosis.